Mineralys Therapeutics, Inc.2024财年第一财季实现净利润-31.51百万美元，同比减少149.88%

自选股智能写手05-19

3月31日，Mineralys Therapeutics, Inc.（MLYS.US）公布财报，公告显示公司2024财年第一财季净利润为-31.51百万美元，同比减少149.88%；其中营业收入为0.00美元，每股基本收益为-0.70美元。从资产负债表来看，Mineralys Therapeutics, Inc.（MLYS.US）总负债19.20百万美元，其中短期债务0.00美元，资产负债比为...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2436811321?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-05-19 00:17","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2436811321","market":"us","top_or_hot":-1,"title":"Mineralys Therapeutics, Inc.2024财年第一财季实现净利润-31.51百万美元，同比减少149.88%","media":"自选股智能写手","content":"<div>\n<p>3月31日，Mineralys Therapeutics, Inc.（MLYS.US）公布财报，公告显示公司2024财年第一财季净利润为-31.51百万美元，同比减少149.88%；其中营业收入为0.00美元，每股基本收益为-0.70美元。从资产负债表来看，Mineralys Therapeutics, Inc.（MLYS.US）总负债19.20百万美元，其中短期债务0.00美元，资产负债比为...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405190017288b15ec41&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mineralys Therapeutics, Inc.2024财年第一财季实现净利润-31.51百万美元，同比减少149.88%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMineralys Therapeutics, Inc.2024财年第一财季实现净利润-31.51百万美元，同比减少149.88%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-19 00:17 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405190017288b15ec41&s=b><strong>自选股智能写手</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>3月31日，Mineralys Therapeutics, Inc.（MLYS.US）公布财报，公告显示公司2024财年第一财季净利润为-31.51百万美元，同比减少149.88%；其中营业收入为0.00美元，每股基本收益为-0.70美元。从资产负债表来看，Mineralys Therapeutics, Inc.（MLYS.US）总负债19.20百万美元，其中短期债务0.00美元，资产负债比为...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405190017288b15ec41&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405190017288b15ec41&s=b","article_id":"2436811321","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405190017288b15ec41&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2436811321","pubTimestamp":1716049035,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"3月31日，Mineralys Therapeutics, Inc.公布财报，公告显示公司2024财年第一财季净利润为-31.51百万美元，同比减少149.88%；其中营业收入为0.00美元，每股基本收益为-0.70美元。机构评级：截至2024年3月31日，当前有6家机构对Mineralys Therapeutics, Inc.目标价做出预测，其中目标均价为33.50美元，其中最低目标价为26.00美元，最高目标价为45.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"LENZ":"Therapeutics","MLYS":"Mineralys Therapeutics, Inc."},"translate_title":"Mineralys Therapeutics, Inc. achieved net profit in the first quarter of fiscal year 2024-US $31.51 million, a year-on-year decrease of 149.88%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"MLYS":1},"content_text":"3月31日，Mineralys Therapeutics, Inc.（MLYS.US）公布财报，公告显示公司2024财年第一财季净利润为-31.51百万美元，同比减少149.88%；其中营业收入为0.00美元，每股基本收益为-0.70美元。从资产负债表来看，Mineralys Therapeutics, Inc.（MLYS.US）总负债19.20百万美元，其中短期债务0.00美元，资产负债比为0.19，流动比率为0.19。机构评级：截至2024年3月31日，当前有6家机构对Mineralys Therapeutics, Inc.目标价做出预测，其中目标均价为33.50美元，其中最低目标价为26.00美元，最高目标价为45.00美元。公司简介：Mineralys Therapeutics Inc 是一家临床阶段的生物制药公司，专注于开发药物以治疗醛固酮异常升高引起的疾病。 该公司的候选产品lorundrostat是一种专有的口服选择性醛固酮合成酶抑制剂，最初开发用于治疗未控制的高血压患者，定义为服用两种或两种以上抗高血压药物或顽固性高血压仍无法将血压降至130/80 mmHg以下的患者。定义为尽管服用了三种或更多种抗高血压药物(通常包括利尿剂)，但仍无法将血压控制在130/80 mmHg以下的个体。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2436811321"}